SCYNEXIS INC - Form 8-K Summary
Business Context and Reporting Period
Date: June 21, 2016
Company: SCYNEXIS, Inc.
Event: Entry into an Equity Underwriting Agreement for a public offering of common stock and warrants.
Key Financial Metrics and Offering Details
- Shares Offered: 9,375,000 shares of common stock.
- Warrants Offered: Warrants to purchase up to 4,218,750 shares (0.45 warrant per share).
- Public Price: $2.40 per share of common stock and accompanying warrant.
- Underwriter Price: $2.256 per share.
- Net Proceeds: Approximately $20.7 million (after underwriting discount and estimated expenses).
- Warrant Terms: Exercise price of $3.00 per share; exercisable immediately; expire five years from issuance.
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares and accompanying warrants.
Material Changes
This filing represents a material capital event rather than a periodic financial performance report. The primary change is the authorization of a new equity issuance to raise capital. The filing does not provide comparative financial data (revenue, profit, cash flow) against prior periods.
Guidance, Outlook, and Risks
- Closing Date: Expected on or about June 24, 2016, subject to customary closing conditions.
- Listing: Shares will be listed on The NASDAQ Global Market.
- Underwriters: Guggenheim Securities, LLC (sole book-running manager); Canaccord Genuity Inc. and Needham & Company (co-lead managers); Brean Capital, LLC (co-manager).
- Risks: Completion of the offering is not assured and depends on market conditions and satisfaction of closing conditions. There is no expected trading market for the warrants.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received.
- Confirm the listing status of the shares on The NASDAQ Global Market.
- Review the final prospectus supplement for any changes to the offering terms.
- Monitor whether the underwriters exercise the over-allotment option within 30 days.
- Check subsequent filings for the use of proceeds and impact on diluted share count.